Project Grant R01AG105060
- The National Institute on Aging awarded The Administrators of Tulane Educational Fund (Tulane University) $871,998 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate accelerated aging in the central nervous system of SIV-infected macaques. The research focuses on astrocyte dysfunction as a central mechanism driving HIV-associated accelerated aging and cognitive decline. The study examines how activated astrocytes in brain regions increase leukocyte transmigration...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $422,125 to the Board of Regents of the University of Nebraska on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the roles of misfolded protein aggregates on latent HIV reservoirs in simian immunodeficiency virus–infected, antiretroviral therapy–treated aged rhesus macaques. The research examines how age-associated amyloid fibril deposition affects the reactivation and...
- The National Institute on Aging awarded Sri International $1.259 million under the Aging Research program (CFDA 93.866) on September 15, 2025, for a project grant investigating glymphatic magnetic resonance imaging and biomarker discovery in aging individuals living with HIV infection through August 31, 2027. The research examines dysfunction of the brain's waste clearance system (the glymphatic system) as a contributor to cognitive decline in older people with HIV. The project uses non-invasive...
- The National Institute on Aging awarded Tulane University four hundred twenty thousand seven hundred fifty dollars on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of L1 retrotransposons in normal brain aging and Alzheimer's disease in vivo. The research tests whether chronic L1 retrotransposon expression contributes to Alzheimer's disease progression using mouse models of L1 retrotransposition and Alzheimer's disease. L1 is a repetitive genetic...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $746,063 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate amyloid beta plaque formation and neuroinflammation in aging people with HIV. The award funds exploration of cell-specific transcriptional changes associated with early amyloid beta deposition in human brain, distinguishing compacted amyloid with early neuritic pathology from diffuse amyloid without neuritic change, and...
- The National Institute on Aging awarded Northwestern University $794,664 under the Aging Research program (CFDA 93.866) on July 15, 2026, to investigate senescence-associated pathways in people living with HIV who experience premature aging. The research targets novel mechanisms of healthy aging in HIV by examining senescence-associated glycan-degrading enzymes (β-galactosidase and sialidase) that degrade anti-inflammatory glycans on circulating glycoproteins, disrupting pathways that inhibit...
- The National Institute on Aging awarded Louisiana State University Health Sciences Center New Orleans $748,679 on August 5, 2026, under the Aging Research program (CFDA 93.866) to conduct an autopsy-based study examining the anti-inflammatory effects of cannabis on Alzheimer's disease-associated neuropathology in people living with HIV. The recipient will analyze full-body autopsy tissues collected from decedents with and without HIV-1 to characterize HIV-1 tissue reservoirs, assess cannabis use...
- The National Institute on Aging awarded the University of Miami $164,766 on September 5, 2026, under the Aging Research program (CFDA 93.866) to conduct research on T cell senescence-driven immune dysfunction in aging and HIV. The research will establish a complete T cell senescence-associated secretory phenotype (SASP) atlas using fluorescence-activated cell sorting and mass spectrometry, then evaluate plasma biomarkers of T cell senescence during physiologic aging and in people with HIV. The...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $1,393,471 on September 19, 2025, under the Aging Research program (CFDA 93.866) to investigate clonal hematopoiesis, epigenetic changes, social determinants of health, and behavioral risk factors as predictors of accelerated aging in people with HIV, with performance through June 30, 2030, in New York, NY. The research examines why people with HIV experience multimorbidities, functional decline, and cognitive...
- The National Institute on Aging awarded the University of California, San Diego $163,867 on July 1, 2026, under the Aging Research program (CFDA 93.866) to discover and classify metabolite biomarkers of neurocognitive impairment in older people with HIV using metabolomics and machine learning methods. The research leverages untargeted metabolomics data from fecal samples of 403 older people with HIV enrolled in cohort studies at UC San Diego's HIV Neurobehavioral Research Center to identify...
The National Institute on Aging, part of the Department of Health and Human Services, awarded Tulane University $874,974 on September 1, 2026, under the Aging Research program (CFDA 93.866) to study the effects of CSF1R blockade on brain aging and HIV-associated neurocognitive disorder using a macaque model. The project examines how neuroinflammation, myeloid dysregulation, and blood-brain barrier decline drive cognitive impairment in aging and HIV infection. The research uses a macaque model for accelerated neuroaging in virally suppressed HIV infection compared with natural aging, and tests brain-penetrant CSF1R inhibitors to ablate activated microglia and macrophages from the brain with the goal of improving neuroinflammation and neurocognition. The work is performed in Covington, Louisiana, with a period of performance extending from September 1, 2026, through May 31, 2031. The award addresses the urgent clinical need for understanding HIV-associated neurocognitive disorder pathogenesis in the context of an aging HIV-positive population. As treated HIV patients live longer and age increases the risk for both HAND and Alzheimer's disease, the research seeks to evaluate an intervention strategy applicable to virally suppressed HIV patients experiencing accelerated neuroaging as well as those aging naturally. Preliminary data and published reports demonstrate the preclinical feasibility of using brain-penetrant CSF1R inhibitors for this purpose.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $875.0k | 8/25/26 |